Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Latest Information Update: 30 Jan 2025
At a glance
- Drugs Birinapant (Primary)
- Indications Head and neck cancer; Human papillomavirus infections; Squamous cell cancer
- Focus Adverse reactions
- 31 Jan 2024 Status changed from active, no longer recruiting to discontinued.
- 10 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2023 Planned End Date changed from 31 Jul 2023 to 31 Jul 2024.